Advertisement

Advertisement
Lung Cancer

FDA Approves Pembrolizumab With Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

The U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma.

Bladder Cancer
Immunotherapy

NIAGARA Trial: Perioperative Durvalumab Reduced Risk of Recurrence or Death vs Neoadjuvant Chemotherapy Alone in Muscle-Invasive Bladder Cancer

Positive results from the phase III NIAGARA trial showed perioperative treatment with the PD-L1 blocker durvalumab in combination with neoadjuvant chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival and the key secondary endpoint of overall survival vs neoadjuvant chemotherapy alone for patients with muscle-invasive bladder cancer. Patients were treated with durvalumab in combination with neoadjuvant chemotherapy before radical cystectomy followed by durvalumab as adjuvant monotherapy.

Hepatobiliary Cancer

5-Year Analysis of Phase III HIMALAYA Confirms Survival Benefit of STRIDE in Hepatocellular Carcinoma

An updated overall survival analysis of the phase III HIMALAYA study, now at 5 years, has confirmed the robust benefit for the STRIDE regimen of durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.At the European Society for Medical Oncology (ESMO) Congress 2024 (Abstract 947MO), investigators reported a doubling of 5-year survival, which was 19.6% with STRIDE vs 9.4% with sorafenib alone—a 24% reduction in the risk of death. This benefit was accentuated in patients achieving disease control, and no additional safety concerns were observed with extended follow-up.

 


Advertisement
Lung Cancer

Taletrectinib in ROS1-Positive NSCLC: Focus on Prior Tyrosine Kinase Inhibitor Exposure Status

Updated data from the global, multicenter, single-arm phase II TRUST-II trial, which were reported by Liu et al during the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC; Abstract MA06.03), continued to demonstrate robust overall and intracranial responses with the next-generation ROS1 tyrosine kinase inhibitor taletrectinib in patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC), regardless of their prior tyrosine kinase inhibitor exposure status and geographic region.

 

 

Gynecologic Cancers

Immunotherapy and Novel Targeted Drug Appear Beneficial in Women With Early-Stage Gynecologic Disease

Studies reported at the European Society for Medical Oncology (ESMO) Congress 2024 reveal new groups of women with early-stage cervical and endometrial cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, and a first-in-human study found “promising” antitumor activity with a novel antibody-drug conjugate targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers.

 

Advertisement
Advertisement




Sponsored Content

SPONSORED BY THE BREAST CANCER INDEX® TEST BIOTHERANOSTICS, INC. A HOLOGIC COMPANY

Extended Endocrine Therapy for Early-Stage Hormone Receptor–Positive Breast Cancer: Tools for Decision-Making

More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC

In a phase III study conducted in China, the bispecific antibody ivonescimab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with the PD-1 inhibitor pembrolizumab as a first-line treatment of PD-L1–positive advanced non–small cell ...

Advertisement

Long-Term Outcomes With Adjuvant Trastuzumab for 9 Weeks or 1 Year in HER2-Positive Breast Cancer: Analysis From SOLD Trial

As reported by Joensuu et al in JAMA Network Open, long-term follow-up of the European SOLD trial indicates the addition of adjuvant trastuzumab to chemotherapy for 9 weeks vs 1 year continued to show poorer disease-free survival in patients with HER2-positive breast cancer, with no difference in...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Global Cancer Care

Prescription for Progress: Lancet Oncology Commission’s Practical Strategies for Global Cancer Surgery

In certain regions of the world, cancer claims more lives than HIV, tuberculosis, and malaria combined, yet surgery has been relegated to the sidelines of global health initiatives. This critical need to address global inequities in access to safe, timely, and affordable cancer surgery led to the...

Lung Cancer

Ifinatamab Deruxtecan Shows Activity in Extensive-Stage Small Cell Lung Cancer

The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (SCLC) in an interim analysis of the phase II IDeate-Lung01 study. The findings were presented at the International Association for the ...

Phase III CABINET Trial: Cabozantinib in Advanced Neuroendocrine Tumors

Cabozantinib may be effective at improving progression-free survival in patients with previously treated neuroendocrine tumors, according to recent findings presented by Chan et al at the European Society for Medical Oncology (ESMO) Congress 2024 (Abstract 1141O) and simultaneously published in The ...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Breast Cancer

Phase III ALEXANDRA/IMpassion030: No Survival Benefit for Adjuvant Atezolizumab in Triple-Negative Breast Cancer

In patients with early-stage triple-negative breast cancer, the addition of atezolizumab to standard adjuvant chemotherapy provided no benefit over chemotherapy alone in the final analysis of the phase III ALEXANDRA/IMpassion030 trial. The results were presented at the 2024 European Breast Cancer...

Advertisement

Immunotherapy Combination May Improve Long-Term Survival in Patients With Metastatic Melanoma

Researchers have found that about 50% of patients with metastatic melanoma treated with a combination of nivolumab and ipilimumab experienced cancer-free survival of 10 years or longer, according to a recent study published by Wolchok et al in The New England Journal of Medicine. Background In...

ASCO Post X Feed
Social Media Hub by Everwall